Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.

Property Value
dbo:abstract
  • Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012. Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits. Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the U.S. From November 2011 until November 2013, the federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies. In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label randomized control trial), which failed to show heart infarct risks associated with the drug. In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks. It was withdrawn from the market in the UK and India in 2010, and in New Zealand and South Africa in 2011. (en)
  • La rosiglitazone, commercialisée sous le nom d'Avandia (r), fait partie d'une classe d'antidiabétique oral apparue sur le marché en 2002 : les thiazolidinediones.Son autorisation de mise sur le marché (AMM) a été suspendue en France et en Europe en septembre 2010 en raison d'importants risques cardiovasculaires. Aux États-Unis, son utilisation a été fortement restreinte par la Food and Drug Administration (FDA) pour les mêmes raisons. (fr)
  • Rosiglitazon ist ein Antidiabetikum aus der Gruppe der Insulin-Sensitizer zur Behandlung des Diabetes mellitus Typ 2. Das Wirkprinzip ist eine Erhöhung der Empfindlichkeit des Gewebes auf Insulin. Das körpereigene Insulin ist folglich wieder effektiver in der Lage, erhöhte Blutzuckerspiegel zu senken. Seit November 2010 ruht auf Anordnung des Bundesinstituts für Arzneimittel und Medizinprodukte (BfArM) in Deutschland die Verkehrsfähigkeit für Arzneimittel mit dem Wirkstoff Rosiglitazon. Ihr Nutzen-Risiko-Verhältnis war seitens des Ausschusses für Humanarzneimittel (CHMP) bei der Europäischen Arzneimittelagentur als insgesamt ungünstig eingestuft worden (kardiovaskuläre Risiken, gehäufte Herzinfarkte). Neuere Studien zeigen jedoch, dass die ursprünglichen Bedenken möglicherweise unbegründet sind, laut einer Überprüfung erhöht Rosiglitazon (Handelsname Avandia) das Herzinfarktrisiko nicht. Die Rohdaten seien in der Originalstudie, die zusätzlich nicht verblindet war, mehr oder weniger bewusst manipuliert worden. Das wirtschaftliche Interesse an der neuerlichen Vermarktung des Medikaments ist aktuell jedoch gering, da das Patent bereits ausgelaufen ist. Rosiglitazon scheint den herkömmlichen Antidiabetika bei höheren Kosten nicht überlegen zu sein. (de)
  • ロシグリタゾン(Rosiglitazone、商品名:アバンディア)はグラクソ・スミスクラインが販売するチアゾリジン系(TZD)抗糖尿病薬である。脂肪細胞のPPAR受容体に結合してインスリン抵抗性を改善する。単剤の製剤の他、メトホルミンとの合剤やグリメピリドとの合剤が有る。副作用情報により、ロシグリタゾンの使用量は劇的に減少した。日本では承認されていない。 (ja)
  • Rozyglitazon (roziglitazon, rosiglitazon, rosiglitazone ATC A10BG) – lek stosowany w leczeniu cukrzycy, należący do doustnych leków hipoglikemizujących (grupa tiazolidinedionów). (pl)
  • Rosiglitazona (maleato) é um fármaco da classe dos antidiabéticos. Teve sua venda proibida na Europa pela EMEA e nos Estados Unidos a venda foi restrita, pelos riscos cardiovasculares que apresenta. No Brasil a Anvisa determinou a retirada do medicamento das farmácias e drogarias, cancelando seu registro em 29 de setembro de 2010. (pt)
  • 罗格列酮(Rosiglitazone)是一種用於控制糖尿病的藥物,商品名稱有:安糖健、文迪雅、梵帝雅(Avandia)等。 製劑為藥片,每片含2mg、4mg或8mg馬來酸罗格列酮(Rosiglitazone maleate)。 (zh)
  • Росиглитазон — лекарственное средство, гипогликемический препарат из группы тиазолидиндионов, селективный агонист ядерных рецепторов PPAR-гамма. (ru)
dbo:atcPrefix
  • A10
dbo:atcSuffix
  • BG02
dbo:bioavailability
  • 99.000000 (xsd:float)
dbo:casNumber
  • 122320-73-4
dbo:chEBI
  • 50122
dbo:drugbank
  • DB00412
dbo:fdaUniiCode
  • 05V02F2KDG
dbo:iupacName
  • (RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione (en)
dbo:pubchem
  • 77999
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 604046 (xsd:integer)
dbo:wikiPageRevisionID
  • 737223378 (xsd:integer)
dbp:c
  • 18 (xsd:integer)
dbp:chembl
  • 121 (xsd:integer)
dbp:chemspiderid
  • 70383 (xsd:integer)
dbp:chirality
dbp:eliminationHalfLife
  • -14400.0
dbp:excretion
  • Renal and fecal
dbp:h
  • 19 (xsd:integer)
dbp:image
  • Rosiglitazone ball-and-stick.png
dbp:iupharLigand
  • 1056 (xsd:integer)
dbp:kegg
  • D00596
dbp:legalUk
  • POM
dbp:legalUs
  • Rx-only
dbp:licenceEu
  • Avandia
dbp:licenceUs
  • Rosiglitazone
dbp:medlineplus
  • a699023
dbp:metabolism
  • Hepatic
dbp:molecularWeight
  • 357.428000 (xsd:double)
dbp:n
  • 3 (xsd:integer)
dbp:o
  • 3 (xsd:integer)
dbp:pdbLigand
  • RGZ
dbp:pregnancyAu
  • B3
dbp:pregnancyUs
  • C
dbp:proteinBound
  • 99.8
dbp:routesOfAdministration
  • Oral
dbp:s
  • 1 (xsd:integer)
dbp:smiles
  • O=C1NCSC1Cc3ccccc3
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • YASAKCUCGLMORW-UHFFFAOYSA-N
dbp:tradename
  • Avandia
dbp:verifiedfields
  • changed
dbp:verifiedrevid
  • 458777178 (xsd:integer)
dbp:width
  • 232 (xsd:integer)
dct:subject
http://purl.org/linguistics/gold/hypernym
rdf:type
rdfs:comment
  • La rosiglitazone, commercialisée sous le nom d'Avandia (r), fait partie d'une classe d'antidiabétique oral apparue sur le marché en 2002 : les thiazolidinediones.Son autorisation de mise sur le marché (AMM) a été suspendue en France et en Europe en septembre 2010 en raison d'importants risques cardiovasculaires. Aux États-Unis, son utilisation a été fortement restreinte par la Food and Drug Administration (FDA) pour les mêmes raisons. (fr)
  • ロシグリタゾン(Rosiglitazone、商品名:アバンディア)はグラクソ・スミスクラインが販売するチアゾリジン系(TZD)抗糖尿病薬である。脂肪細胞のPPAR受容体に結合してインスリン抵抗性を改善する。単剤の製剤の他、メトホルミンとの合剤やグリメピリドとの合剤が有る。副作用情報により、ロシグリタゾンの使用量は劇的に減少した。日本では承認されていない。 (ja)
  • Rozyglitazon (roziglitazon, rosiglitazon, rosiglitazone ATC A10BG) – lek stosowany w leczeniu cukrzycy, należący do doustnych leków hipoglikemizujących (grupa tiazolidinedionów). (pl)
  • Rosiglitazona (maleato) é um fármaco da classe dos antidiabéticos. Teve sua venda proibida na Europa pela EMEA e nos Estados Unidos a venda foi restrita, pelos riscos cardiovasculares que apresenta. No Brasil a Anvisa determinou a retirada do medicamento das farmácias e drogarias, cancelando seu registro em 29 de setembro de 2010. (pt)
  • 罗格列酮(Rosiglitazone)是一種用於控制糖尿病的藥物,商品名稱有:安糖健、文迪雅、梵帝雅(Avandia)等。 製劑為藥片,每片含2mg、4mg或8mg馬來酸罗格列酮(Rosiglitazone maleate)。 (zh)
  • Росиглитазон — лекарственное средство, гипогликемический препарат из группы тиазолидиндионов, селективный агонист ядерных рецепторов PPAR-гамма. (ru)
  • Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis published in the New England Journal of Medicine in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012. (en)
  • Rosiglitazon ist ein Antidiabetikum aus der Gruppe der Insulin-Sensitizer zur Behandlung des Diabetes mellitus Typ 2. Das Wirkprinzip ist eine Erhöhung der Empfindlichkeit des Gewebes auf Insulin. Das körpereigene Insulin ist folglich wieder effektiver in der Lage, erhöhte Blutzuckerspiegel zu senken. Rosiglitazon scheint den herkömmlichen Antidiabetika bei höheren Kosten nicht überlegen zu sein. (de)
rdfs:label
  • Rosiglitazone (en)
  • Rosiglitazon (de)
  • Rosiglitazone (fr)
  • ロシグリタゾン (ja)
  • Rozyglitazon (pl)
  • Rosiglitazona (pt)
  • Росиглитазон (ru)
  • 罗格列酮 (zh)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of